TR201821158T4 - Triazin bileşiği ve bunun tıbbi amaçlarla kullanımı. - Google Patents

Triazin bileşiği ve bunun tıbbi amaçlarla kullanımı. Download PDF

Info

Publication number
TR201821158T4
TR201821158T4 TR2018/21158T TR201821158T TR201821158T4 TR 201821158 T4 TR201821158 T4 TR 201821158T4 TR 2018/21158 T TR2018/21158 T TR 2018/21158T TR 201821158 T TR201821158 T TR 201821158T TR 201821158 T4 TR201821158 T4 TR 201821158T4
Authority
TR
Turkey
Prior art keywords
triazine compound
medical purposes
compound
disease
cancer
Prior art date
Application number
TR2018/21158T
Other languages
English (en)
Inventor
Nagamori Hironobu
Mitani Ikuo
Yamashita Masaki
hotta Takahiro
Nakagawa Yuichi
Ueda Masatoshi
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of TR201821158T4 publication Critical patent/TR201821158T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

mPGES-1 inhibitör aktiviteye sahip ve ağrı, romatizma, osteoartrit, ateş, Alzheimer hastalığı, multipl skleroz, arteriyoskleroz, glokom, oküler hipertansiyon, iskemik retinal hastalık, sistemik skleroderma ve kolorektal kanser dahil kanser profilaksı veya tedavisi için faydalı bir bileşik sunulur. Formül [I] ile temsil edilen bir bileşik veya bunun farmasötik açıdan kabul edilebilir bir tuzu: buradaki her sembol, SPESİFİKASYONDA tanımlandığı gibidir.
TR2018/21158T 2014-02-20 2015-02-19 Triazin bileşiği ve bunun tıbbi amaçlarla kullanımı. TR201821158T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014031035 2014-02-20

Publications (1)

Publication Number Publication Date
TR201821158T4 true TR201821158T4 (tr) 2019-01-21

Family

ID=53878341

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/21158T TR201821158T4 (tr) 2014-02-20 2015-02-19 Triazin bileşiği ve bunun tıbbi amaçlarla kullanımı.

Country Status (31)

Country Link
US (3) US20150266834A1 (tr)
EP (2) EP3456713A1 (tr)
JP (4) JP6461637B2 (tr)
KR (1) KR102360699B1 (tr)
CN (1) CN106232585B (tr)
AR (1) AR099498A1 (tr)
AU (1) AU2015219920B2 (tr)
BR (1) BR112016018341B1 (tr)
CA (1) CA2936408C (tr)
CL (1) CL2016002091A1 (tr)
CY (1) CY1121261T1 (tr)
DK (1) DK3109240T3 (tr)
ES (1) ES2704922T3 (tr)
HR (1) HRP20182134T1 (tr)
IL (1) IL247319B (tr)
LT (1) LT3109240T (tr)
MX (1) MX369217B (tr)
MY (1) MY183605A (tr)
PE (2) PE20211548A1 (tr)
PH (1) PH12016501651B1 (tr)
PL (1) PL3109240T3 (tr)
PT (1) PT3109240T (tr)
RS (1) RS58235B1 (tr)
RU (1) RU2692789C2 (tr)
SA (1) SA516371701B1 (tr)
SG (1) SG11201606902QA (tr)
SI (1) SI3109240T1 (tr)
TR (1) TR201821158T4 (tr)
TW (1) TWI651310B (tr)
WO (1) WO2015125842A1 (tr)
ZA (1) ZA201606449B (tr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
AU2015371822B2 (en) * 2014-12-24 2020-04-09 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
JP6478255B2 (ja) * 2015-03-04 2019-03-06 株式会社島津製作所 蛍光誘導体化試薬及びアミン分析方法
CN108137515B (zh) * 2015-08-17 2021-07-06 日本烟草产业株式会社 羟基三嗪化合物和其医药用途
SG10201913525QA (en) * 2015-10-29 2020-02-27 Aska Pharmaceutical Co Ltd Pyrimidine derivative
GB201603311D0 (en) * 2016-02-25 2016-04-13 Jakobsson Per Johan New uses and methods
PE20190500A1 (es) * 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y uso de los mismos
EP3645527A1 (de) * 2017-06-26 2020-05-06 Merck Patent GmbH Verfahren zur herstellung substituierter stickstoffhaltiger heterocyclen
US20220281841A1 (en) * 2019-07-22 2022-09-08 Angion Biomedica Corp. Ethynylheterocycles as rho-associated coiled-coil kinase (rock) inhibitors
US11786538B2 (en) * 2019-12-11 2023-10-17 Somerset Therapeutics, Llc Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties
KR102157466B1 (ko) * 2020-05-19 2020-09-17 동아대학교 산학협력단 헥사하이드로트리아진 유도체를 포함하는 방광암의 예방, 개선 또는 치료용 조성물
US20240083867A1 (en) 2021-02-02 2024-03-14 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0051067A1 (en) * 1980-04-22 1982-05-12 Commonwealth Scientific And Industrial Research Organisation Triazine synthesis
DE19543730A1 (de) * 1995-11-23 1997-05-28 Ciba Geigy Ag Bis-Resorcinyl-Triazine
HUP0001698A3 (en) * 1996-12-05 2002-07-29 Amgen Inc Thousand Oaks Substituted pyrimidine compounds and their use
WO1998024782A2 (en) * 1996-12-05 1998-06-11 Amgen Inc. Substituted pyrimidine compounds and their use
AU2003245669A1 (en) * 2002-06-21 2004-01-06 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
EP2138488A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
CN101747282A (zh) * 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
EP2488032B1 (en) * 2009-09-23 2016-11-02 Albert Einstein College of Medicine, Inc. Prostaglandin transporter inhibitors and uses thereof
AR086254A1 (es) * 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
FR2983859B1 (fr) * 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
AU2013207289B2 (en) * 2012-01-06 2017-09-21 Les Laboratoires Servier Therapeutically active compounds and their methods of use
TWI568722B (zh) * 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
JP2014031035A (ja) 2012-08-01 2014-02-20 Yamaha Motor Co Ltd 原動機付き鞍乗型車両
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
CN105586773A (zh) * 2014-11-13 2016-05-18 东丽纤维研究所（中国）有限公司 一种拒水抗紫外纺织品及其生产方法和用途

Also Published As

Publication number Publication date
KR102360699B1 (ko) 2022-02-10
US20230011968A1 (en) 2023-01-12
PT3109240T (pt) 2019-01-21
PH12016501651A1 (en) 2017-02-06
CA2936408C (en) 2022-09-13
PE20161236A1 (es) 2016-11-23
WO2015125842A1 (ja) 2015-08-27
CA2936408A1 (en) 2015-08-27
TWI651310B (zh) 2019-02-21
EP3109240A4 (en) 2017-07-26
JP2021054856A (ja) 2021-04-08
PH12016501651B1 (en) 2017-02-06
BR112016018341B1 (pt) 2023-02-07
JP2022120173A (ja) 2022-08-17
BR112016018341A2 (tr) 2017-08-08
IL247319B (en) 2019-11-28
IL247319A0 (en) 2016-09-29
RU2692789C2 (ru) 2019-06-27
EP3109240A1 (en) 2016-12-28
CN106232585A (zh) 2016-12-14
US20150266834A1 (en) 2015-09-24
AR099498A1 (es) 2016-07-27
RS58235B1 (sr) 2019-03-29
LT3109240T (lt) 2019-01-10
SI3109240T1 (sl) 2019-02-28
HRP20182134T1 (hr) 2019-02-08
RU2016137263A (ru) 2018-03-23
AU2015219920B2 (en) 2018-12-20
AU2015219920A1 (en) 2016-07-14
MX369217B (es) 2019-10-31
PE20211548A1 (es) 2021-08-16
DK3109240T3 (en) 2018-12-17
US20200087266A1 (en) 2020-03-19
SG11201606902QA (en) 2016-09-29
ES2704922T3 (es) 2019-03-20
NZ721718A (en) 2021-08-27
JP2019065036A (ja) 2019-04-25
SA516371701B1 (ar) 2019-01-21
MX2016010875A (es) 2016-10-26
RU2016137263A3 (tr) 2018-10-04
PL3109240T3 (pl) 2019-03-29
CY1121261T1 (el) 2020-05-29
EP3109240B1 (en) 2018-10-24
KR20160113727A (ko) 2016-09-30
TW201620881A (zh) 2016-06-16
JP2015172039A (ja) 2015-10-01
EP3456713A1 (en) 2019-03-20
CL2016002091A1 (es) 2017-01-20
MY183605A (en) 2021-03-02
ZA201606449B (en) 2017-11-29
JP6461637B2 (ja) 2019-01-30
CN106232585B (zh) 2019-04-02

Similar Documents

Publication Publication Date Title
TR201821158T4 (tr) Triazin bileşiği ve bunun tıbbi amaçlarla kullanımı.
CY1119487T1 (el) Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
CY1123353T1 (el) Καινοφανης ενωση συμπυκνωμενης πυριμιδινης ή αλας εξ αυτης
EA201891049A1 (ru) Изоиндолиновые, азаизоиндолиновые, дигидроинденоновые и дигидроазаинденоновые ингибиторы mnk1 и mnk2
EA201990833A1 (ru) Соединение пиридина
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
CY1124078T1 (el) Συνθεσεις που περιλαμβανουν αναστολεα λυσινης ειδικης απομεθυλασης-1 που εχει δακτυλιο πυριμιδινης και χρηση αυτων στη θεραπεια καρκινου
CA2925624C (en) Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
CY1120907T1 (el) Αντιμυκητιασικοι παραγοντες
MX2016001011A (es) Derivados de quinazolin-4-ona sustituida.
EA202192151A1 (ru) Применение пиразолпиримидиновых производных для лечения нарушений, связанных с pi3k
MD4812C1 (ro) Derivaţi nucleozidici 4'-substituiţi în calitate de inhibitori ai transcriptazei inverse a HIV
AR101403A1 (es) (4s)-4-(4-ciano-2-metoxifenilo)-5-etoxi-2,8-dimetilo-1,4-dihidro-1,6-naftiridin-3-carboxamida, su purificación para su uso como principio activo farmacéutico, un procedimiento para su preparación y su empleo en el tratamiento de enfermedades cardiovasculares
WO2017087808A8 (en) Heterocyclic compounds that inhibit the kinase activity of mnk useful for treating various cancers
CY1120836T1 (el) Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
PH12017500095A1 (en) Imidazopyridazine compounds
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
BR112018001809A2 (pt) composto de hidroxitriazina e uso médico do mesmo
CY1120608T1 (el) Φαρμακευτικως δραστικες ενωσεις
PH12015502744A1 (en) Bicyclic nitrogen-containing aromatic heterocyclic amide compound
PH12016501645A1 (en) Aminopyrazolone derivative
TR201910158T4 (tr) İmmün hastalıklara yönelik önleyici ve/veya terapötik ajan.
EA201692371A1 (ru) 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений
WO2019040104A3 (en) COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES